Skip to content

Ofatumumab

Arzerra, Kesimpta (ofatumumab) is an antibody pharmaceutical. Ofatumumab was first approved as Arzerra on 2009-10-26. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name Kesimpta
Common Name Ofatumumab
Indication lymphoid leukemia, relapsing-remitting multiple sclerosis
Drug Class Monoclonal antibodies
Ofatumumab
Get full access now